Abstract
Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase (ALK) gene is an oncogenic driver in approximately 5% of patients with non-small cell lung carcinoma (NSCLC). This review describes the discovery of the ALK translocation, development of ALK directed therapy, and acquired resistance to ALK directed therapy with a focus on the clinical data and efficacy of the most recently approved ALK inhibitor, ceritinib.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 236-241 |
| Number of pages | 6 |
| Journal | Therapeutic Advances in Respiratory Disease |
| Volume | 9 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 2015 |
Keywords
- ALK translocation
- NSCLC
- ceritinib
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS